21st Dec 2006 13:11
Hikma Pharmaceuticals Plc21 December 2006 Hikma Pharmaceuticals PLC - Voting Rights and Capital LONDON, 21 December 2006 - In conformity with the Transparency Directive'stransitional provision 6 we would like to notify the market of the following: Hikma Pharmaceuticals PLC's capital consists of 168,164,207 ordinary shares withvoting rights. The above figure (168,164,207) may be used by shareholders as the denominatorfor the calculations by which they will determine if they are required to notifytheir interest in, or a change to their interest in, Hikma Pharmaceuticals PLCunder the FSA's Disclosure and Transparency Rules. - ENDS -Enquiries: Hikma Pharmaceuticals PLC Susan Ringdal +44 20 7399 2760Investor Relations Director Brunswick GroupJon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959 About HikmaHikma Pharmaceuticals PLC is a multinational pharmaceutical group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: Generic, Branded and InjectablePharmaceuticals. Hikma's operations are based principally in the United States,the Middle East and North Africa ("MENA") region and Europe. In 2005, the Grouphad revenue of $262 million and profit attributable to shareholders of $44million. At 31 December 2005, the Group had over 1,800 employees. For news andother information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Hikma Pharmaceuticals